Literature DB >> 12917446

Alphavbeta6-Fyn signaling promotes oral cancer progression.

Xiaowu Li1, Yongjian Yang, Yongmei Hu, Dongmin Dang, Joseph Regezi, Brian L Schmidt, Amha Atakilit, Bing Chen, Duncan Ellis, Daniel M Ramos.   

Abstract

We have previously shown that the integrin beta6 is neo-expressed in invasive oral squamous cell carcinoma (SCC) and is correlated with oral tumor progression. However, the mechanism by which the integrin beta6 promotes oral tumor progression is not well understood. The purpose of the present study was to determine whether integrin beta6 signaling activates Fyn and thus promotes oral squamous cell carcinoma progression. We analyzed the integrin beta6 signaling complex and investigated the function of these signaling molecules in oral SCC cells. We found that, upon ligation of the integrin beta6 with fibronectin, beta6 complexed with Fyn and activated it. The activation of Fyn recruited and activated focal adhesion kinase to this complex. This complex was necessary to activate Shc and to couple beta6 signaling to the Raf-ERK/MAPK pathway. This pathway transcriptionally activated the matrix metalloproteinase-3 gene and promoted oral SCC cell proliferation and experimental metastasis in vivo. These findings indicate that integrin beta6 signaling activates Fyn and thus promotes oral cancer progression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12917446     DOI: 10.1074/jbc.M306274200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

1.  Genetic variants at 2q24 are associated with susceptibility to type 2 diabetes.

Authors:  Lu Qi; Marilyn C Cornelis; Peter Kraft; Kristopher J Stanya; W H Linda Kao; James S Pankow; Josée Dupuis; Jose C Florez; Caroline S Fox; Guillaume Paré; Qi Sun; Cynthia J Girman; Cathy C Laurie; Daniel B Mirel; Teri A Manolio; Daniel I Chasman; Eric Boerwinkle; Paul M Ridker; David J Hunter; James B Meigs; Chih-Hao Lee; Frank B Hu; Rob M van Dam
Journal:  Hum Mol Genet       Date:  2010-04-23       Impact factor: 6.150

2.  The αvβ6 integrin is transferred intercellularly via exosomes.

Authors:  Carmine Fedele; Amrita Singh; Brad J Zerlanko; Renato V Iozzo; Lucia R Languino
Journal:  J Biol Chem       Date:  2015-01-07       Impact factor: 5.157

3.  Characterization and evaluation of (64)Cu-labeled A20FMDV2 conjugates for imaging the integrin αvβ 6.

Authors:  Lina Y Hu; Nadine Bauer; Leah M Knight; Zibo Li; Shuanglong Liu; Carolyn J Anderson; Peter S Conti; Julie L Sutcliffe
Journal:  Mol Imaging Biol       Date:  2014-08       Impact factor: 3.488

4.  Role of integrins in regulating proteases to mediate extracellular matrix remodeling.

Authors:  Jiao Yue; Kun Zhang; Jianfeng Chen
Journal:  Cancer Microenviron       Date:  2012-03-22

5.  Transforming growth factor-β1 enhances proliferative and metastatic potential by up-regulating lymphoid enhancer-binding factor 1/integrin αMβ2 in human renal cell carcinoma.

Authors:  Yuting Liu; Donghao Shang
Journal:  Mol Cell Biochem       Date:  2019-12-17       Impact factor: 3.396

Review 6.  Targeting Fyn Kinase in Alzheimer's Disease.

Authors:  Haakon B Nygaard
Journal:  Biol Psychiatry       Date:  2017-06-13       Impact factor: 13.382

7.  Binding of Herpes Simplex Virus 1 UL20 to GODZ (DHHC3) Affects Its Palmitoylation and Is Essential for Infectivity and Proper Targeting and Localization of UL20 and Glycoprotein K.

Authors:  Shaohui Wang; Kevin R Mott; Kolja Wawrowsky; Konstantin G Kousoulas; Bernhard Luscher; Homayon Ghiasi
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

Review 8.  Defining the role of integrin alphavbeta6 in cancer.

Authors:  A Bandyopadhyay; S Raghavan
Journal:  Curr Drug Targets       Date:  2009-07       Impact factor: 3.465

9.  Identification of tetranectin as a potential biomarker for metastatic oral cancer.

Authors:  Martha E Arellano-Garcia; Roger Li; Xiaojun Liu; Yongming Xie; Xiaofei Yan; Joseph A Loo; Shen Hu
Journal:  Int J Mol Sci       Date:  2010-09-02       Impact factor: 5.923

10.  Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors.

Authors:  Ann Marie Egloff; Jennifer Rubin Grandis
Journal:  J Oncol       Date:  2009-07-14       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.